Artificial Intelligence: Shaping Next Generation Oncotherapy
Cancer Bioscience · 2026
DOI: 10.1016/j.cbs.2026.100007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Bioscience, 2026. Verfasst von Kamuju Tejashwini und 4 weiteren Autor:innen. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer is one of the urgent global health challenges, with millions of lives lost each year. In medical technology, cancer is a multifactorial and dynamic disease and a complex process. It remains a formidable challenge for clinicians, healthcare workers, medical & pharmaceutical scientists, and patients despite notable advancements in understanding its biological aspects. Recent literature reports suggest that artificial intelligence has emerged as a paradigm-shifting tool across the medical field, medical image interpretation, personalized care, and the drug development pipeline. In oncology, working with large datasets poses significant challenges, including data management, ensuring data quality assurance, and protecting privacy. The Artificial intelligence-assisted cancer therapy is increasingly likened to a new technological, medical, and pharmaceutical industrial revolution. There are two important components of AI, which include machine learning and deep learning, useful in cancer therapy. They are involved in many tasks such as organ classification, accurate dose prediction, and therapy plan optimization. Artificial intelligence and robotics are revolutionizing the healthcare sector by enabling more precise and personalized medicine and surgical strategies, resulting in improved outcomes. Moreover, the examination of large clinical datasets using AI accelerates the identification of eligible clinical trial participants, the prediction of therapeutic responses, and the optimization of trial design, ultimately accelerating the development of novel therapies. AI can also simplify complex processes for doctors and support better, evidence-based treatment decisions. Looking ahead, the future of precision oncology will depend on the use of AI to integrate diverse biological data.
Zitieren
APA
Tejashwini, K., Thota, S., Himabindu, V., Maneesha, N., & Bhukya, B. R. (2026). Artificial Intelligence: Shaping Next Generation Oncotherapy. Cancer Bioscience. https://doi.org/10.1016/j.cbs.2026.100007
Vancouver
Tejashwini K, Thota S, Himabindu V, Maneesha N, Bhukya BR. Artificial Intelligence: Shaping Next Generation Oncotherapy. Cancer Bioscience. 2026. doi:10.1016/j.cbs.2026.100007
BibTeX
@article{Tejashwini2026,
author = {Tejashwini, Kamuju and Thota, Sreekanth and Himabindu, Vainala and Maneesha, Naraveni and Bhukya, Babu Rao},
title = {Artificial Intelligence: Shaping Next Generation Oncotherapy},
journal = {Cancer Bioscience},
year = {2026},
doi = {10.1016/j.cbs.2026.100007}
}
EUVIMED